Huilai Zhang

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard, Marek Trněný, Koji Izutsu et al. · Journal of Clinical Oncology · 2019 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Longyun Chen, Mattias Berglund, Weicheng Ren et al. · Blood · 2016 · 201 citations

Medicine, Genetics, Molecular Genetics +16

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 183 citations

Medicine, Oncology, Pharmacology +17

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 169 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 157 citations · Full text

Medicine, Oncology, Pharmacotherapy +17